Kailera Therapeutics (NASDAQ:KLRA) Stock Picked Up by Analysts at Canaccord Genuity Group

Investment analysts at Canaccord Genuity Group initiated coverage on shares of Kailera Therapeutics (NASDAQ:KLRA) in a research report issued to clients and investors on Monday, Briefing.com reports. The brokerage set a “buy” rating and a $44.00 price target on the stock. Canaccord Genuity Group‘s price objective points to a potential upside of 239.24% from the stock’s current price.

Separately, Weiss Ratings raised Kailera Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $43.00.

Kailera Therapeutics Price Performance

Shares of NASDAQ KLRA opened at $12.97 on Monday. Kailera Therapeutics has a twelve month low of $9.76 and a twelve month high of $28.23. The company has a fifty day moving average price of $12.78. The firm has a market capitalization of $1.68 billion and a PE ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last posted its earnings results on Wednesday, November 4th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.55) by $0.81. As a group, analysts expect that Kailera Therapeutics will post -3.89 EPS for the current year.

Hedge Funds Weigh In On Kailera Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Frazier Life Sciences Management L.P. acquired a new stake in shares of Kailera Therapeutics in the second quarter valued at $24,233,000. State Street Corp purchased a new position in Kailera Therapeutics in the second quarter valued at $19,126,000. Atlas Venture Life Science Advisors LLC acquired a new position in Kailera Therapeutics during the 2nd quarter worth $113,923,000. Wellington Management Group LLP acquired a new position in Kailera Therapeutics during the 2nd quarter worth $64,308,000. Finally, Mirador Capital Partners LP purchased a new stake in Kailera Therapeutics during the 3rd quarter worth about $666,000.

About Kailera Therapeutics

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and related metabolic diseases.

The company’s activities center on the research and development of potential pharmaceutical therapies intended to address chronic weight management and associated health conditions. Its products remain in development and are subject to clinical, regulatory and commercial milestones.

Publicly available information about Kailera Therapeutics’ specific product candidates, operating geographies and leadership is limited.